期刊文献+

^(18)F-FDG PET/CT双时相显像在诊断膀胱癌术后复发和转移中的价值 被引量:6

Value of the dual phase18F-FDG PET / CT in the diagnosis of recurrent and metastatic bladder cancer after surgery
下载PDF
导出
摘要 目的:探讨18F-FDG PET/CT双时相显像诊断膀胱癌术后复发和转移灶的应用价值。方法:膀胱癌术后患者84例,其中临床可疑膀胱癌复发者16例,可疑转移者24例,无临床症状者44例。18F-FDG PET/CT检查时间为术后0.5~240个月,中位时间11.5个月。所有患者18F-FDG PET/CT常规全身显像后,口服40 mg呋塞米并多饮水,多次排尿,服呋塞米后约2 h憋尿充盈膀胱,再进行18F-FDG PET/CT盆腔延迟显像。膀胱癌复发病灶和转移灶的确诊,依据病理组织学检查结果或6个月以上的病例随访结果。结果:18F-FDG PET/CT显像诊断膀胱癌复发病灶的灵敏度、特异性、准确度、阳性预测值、阴性预测值分别为91.7%(22/24)、95.0%(57/60)、94.0%(79/84)、88.0%(22/25)、96.6%(57/59);诊断膀胱癌转移病灶的灵敏度、特异性、准确度、阳性预测值、阴性预测值分别为90.0%(27/30)、96.3%(52/54)、94.0%(79/84)、93.1%(27/29)、94.5%(52/55)。结论 :18F-FDG PET/CT双时相显像可以灵敏地检出膀胱癌术后的复发和转移灶,对膀胱癌术后随访及再分期具有重要的临床应用价值。 Objective To investigate the clinical value of dual phase 18F-FDG PET/CT in the diagnosis of recurrent and metastatic bladder cancer after surgery. Methods The imaging data from 84 patients underwent the dual phase 18F-FDG PET/CT after surgery with known histories of bladder cancer were analyzed. Among the 84 patients, 16 had symptoms of recurrence, 24 had symptoms of metastasis and 44 didn't have any symptom. The median interval time between the primary tumor resection and the PET/CT scan was 11.5 months (0.5 - 240 months). According to the PET/CT imaging procedures, all patients underwent whole body PET/CT scan at 60 minutes after IV injection of 18F-FDG. Additional delayed pelvic PET/CT images were acquired after forced diuresis by using oral 40 mg furosemide. The 18F-FDG PET/CT findings were compared with histopathologic examination results and (or) the clinical follow-up. All patients were followed up for more than six months. Results Results of detecting recurrence and metastasis of bladder cancer showed that the sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the dual phase FDG PET/CT imaging protocol were 91.7%(22/24), 95.0%(57/60), 94.0%(79/ 84), 88.0%(22/25), 96.6%(57/59) and 90.0%(27/30), 96.3%(52/54), 94.0%(79/84), 93.1%(27/29), 94.5% (52/55), respectively. Conclusion Dual phase FDG PET/CT can be used to detect the recurrence and metastasis with high accuracy, contributing to the restaging and follow-up in bladder cancer after surgery.
出处 《实用医学杂志》 CAS 北大核心 2014年第9期1450-1453,共4页 The Journal of Practical Medicine
基金 国家自然科学基金(编号:81271645 81071174) 广东省医学科研基金(编号:B2010189)
关键词 膀胱肿瘤 复发 转移 体层摄影术 发射型计算机 脱氧葡萄糖 Urinary bladder neoplasms Recurrence Metastasis Tomography, emission-computed Deoxyglucose
  • 相关文献

参考文献11

  • 1Siegel RL, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014,64( 1 ) :9-29.
  • 2雷鸣,崔书中,巴明臣.热灌注化疗治疗膀胱癌的研究进展[J].实用医学杂志,2012,28(2):169-171. 被引量:7
  • 3Witjes JA, Comp6rat E, Cowan NC, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines [J]. Eur Urol, 2014,65(4):778-792.
  • 4Harney JV, Wahl RL, Liebert M, et al. Uptake of 2-deoxy, 2- (18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography [J]. J Urol, 1991,145(2) :279-283.
  • 5Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribation of [ 18F] 2-deoxy-2- fluoro-D-glucose [J]. J Nucl Med, 1978,19(10) : 1154-1161.
  • 6Kim S, Chung JK, Kim BT, et al. Relationship between gastrointestinal F- I 8-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET [J]. Clin Positron Imaging, 1999,2 (5) : 273-279.
  • 7Yossepowitch O, Dalbagni G, Golijanin D, et al. Orthotopic urinary diversion after cystectomy for bladder cancer:implications for cancer control and patterns of disease recurrence [J]. J Urol, 2003,169( 1 ) : 177-181.
  • 8Mertens LS, Mir MC, Scott AM, et al. 18F-fluorodeoxyglucose- positron emission tomograpby/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer [J]. Urology, 2014,83 (2) : 393-398.
  • 9Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta- analysis [J]. Eur J Radiol, 2012,81 (9) : 2411-2416.
  • 10Drieskens O, Oyen R, Van Poppel H, et al. FDG-PET for preoperative staging of bladder cancer [J]. Eur J Nucl Med Mol Imaging, 2005,31 (12) : 1412-1417.

二级参考文献14

  • 1李鼎九,张珊文.哺乳动物加温后细胞分子水平[M]//李鼎九,胡自省,钟毓斌.肿瘤热疗学.2版.郑州:郑州大学出版社.2003:25-34.
  • 2Colombo R, Salonia A, Da Pozzo L F, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience[J]. Crit Rev Oncol Hematol., 2003,47 (2) : 127-139.
  • 3Colombo R, Da Pozzo L F, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma[J]. J Clin Oncol, 2003, 21 (23) :4270-4276.
  • 4Gofrit O N, Shapiro A, Pode D, et al. Combined local bladder hyperthermia and intravesieal chemotherapy for the treatment of high-grade superficial bladder cancer [J]. Urology, 2004,63 (3) :466-471.
  • 5Van der Heijden A G, Kiemeney L A, Gofrit 0 N, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder [J]. Eur-Urol, 2004,46(1): 65-71.
  • 6Moskovitz B, Meyer G, Kravtzov A, et al. Thermo- chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients [ J ]. Ann Oncol, 2005,16 (4) : 585 - 589.
  • 7Van der Heijden A G, Hulsbergen-Van de Kaa C A, Witjes J A, et al. The infuence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis [J]. World J Urol, 2007,25 (3) : 303-308.
  • 8Halachmi S, Moskovitz B, Maffezzini M,et al.Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder [J]. Urol Oncol, 2011,29(3) :259-264.
  • 9Nativ O, Witjes J A, Hendricksen K, et al. CombinedThermo- Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin [J]. J Urology, 2009,182(4) : 1313-1317.
  • 10Witjes J A, Hendricksen K, Gofrit O, er al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of theurinary bladder: experience of the European Synergo working oartv[J]. World J Uml. 2009.27(3):319-324.

共引文献6

同被引文献47

  • 1蒋明慧,叶元.子宫内膜癌筛查在临床中的应用分析[J].世界最新医学信息文摘,2020(27):131-133. 被引量:1
  • 2窦恒利,许孝新,王燕,程惠新.APRIL mRNA在食管鳞癌组织中的表达及意义[J].山东医药,2008,48(5):68-69. 被引量:2
  • 3吴湖炳,王全师,王明芳,王欣璐,郭晓君.呋塞米介入试验在泌尿生殖系统肿瘤^(18)F-FDG PET/CT显像中的应用[J].中华核医学杂志,2005,25(4):206-208. 被引量:23
  • 4王唯一,毛振彪,潘正平,黄介飞,邵建国.人胰腺癌组织中增殖诱导配体蛋白的表达及意义[J].第二军医大学学报,2007,28(2):214-215. 被引量:11
  • 5丰有吉,沈铿.妇产科学[M].2版.北京:人民卫生出版社,2010:325.
  • 6WanQ, JiaoQ, LiX, et al. Value of 18F-FDG PET/CT and MRI in diagnosing primary endometrial small cell carcinoma[J]. Chin J Cancer Res, 2014, 26(5):627-631. DOI:10.3978/j.issn.1000-9604.2014.10.04.
  • 7LaiCH, LinG, YenTC, et al. Molecular imaging in the management of gynecologic malignancies[J]. Gynecol Oncol, 2014, 135(1):156-162. DOI:10.1016/j.ygyno.2014.07.092.
  • 8SharmaP, KumarR, SinghH, et al. Carcinoma endometrium: role of 18F-FDG PET/CT for detection of suspected recurrence[J]. Clin Nucl Med, 2012, 37(7):649-655. DOI:10.1097/RLU.0b013e31824d24fa.
  • 9KadkhodayanS, ShahriariS, TregliaG, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature[J]. Gynecol Oncol, 2013, 128(2):397-404. DOI:10.1016/j.ygyno.2012.10.022.
  • 10RyuSY, KimK, KimY, et al. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease[J]. J Korean Med Sci, 2010, 25(7):1029-1033. DOI:10.3346/jkms.2010.25.7.1029.

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部